Alberta Veterinary Laboratories Ltd. – Trademark Portfolio

Entity Type: 03

Alberta Veterinary Laboratories Ltd. holds 20 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 20 filings in this category. Currently, 15 trademarks are registered and 2 are pending. Notable registered marks include SOLOX, SOLVET, BOVI MV, LIDOCAM, and LIDOBAND. The owner is based in Calgary, Alberta.

7226 107th Ave SE.

Calgary, Alberta T2C5N6 , CA

20 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Alberta Veterinary Laboratories Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (20 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Alberta Veterinary Laboratories Ltd. have?

Alberta Veterinary Laboratories Ltd. has 20 U.S. trademarks filed with the USPTO. Of these, 15 registered, 2 pending, 3 abandoned.

What trademark classes does Alberta Veterinary Laboratories Ltd. file in?

Alberta Veterinary Laboratories Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Alberta Veterinary Laboratories Ltd.'s most well-known trademarks?

Alberta Veterinary Laboratories Ltd.'s registered trademark portfolio includes well-known marks such as SOLOX, SOLVET, BOVI MV, LIDOCAM, and LIDOBAND. These are among 15 currently registered trademarks in the portfolio.

What is Alberta Veterinary Laboratories Ltd.'s trademark registration success rate?

Alberta Veterinary Laboratories Ltd. has a 83% trademark registration rate, with 15 out of 18 resolved applications resulting in successful registration. Currently, 2 applications are pending review.